ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "immunology"

  • Abstract Number: 0449 • ACR Convergence 2020

    Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca

    Blake Warner1, Billel Gasmi2, David Kleiner3, Paola Perez Riveros4, Daniel Barber5, Shunsuke Sakai5 and Alan Baer6, 1National Institute of Dental and Craniofacial Research, Bethesda, 2National Cancer Institute, Bethesda, MD, 3National Cancer Institute, Bethesda, 4National Institute of Dental and Craniofacial Research, Bethesda, MD, 5National Institute of Allergy and Infectious Disease, Bethesda, MD, 6Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Immune checkpoint inhibitors (ICI) have advanced the field of cancer therapeutics. By blocking the negative co-stimulation of T cells, ICI augment the anti-tumor immune…
  • Abstract Number: 0843 • ACR Convergence 2020

    Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus

    Nick Huang1, Akshay Patel1, Zachary Oaks1 and Andras Perl1, 1SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: HRES-1/Rab4 or Rab4A, a GTPase responsible for mitochondrial oxidative stress1 and activation of the mechanistic target of rapamycin2, is overexpressed in T cells of…
  • Abstract Number: 1568 • ACR Convergence 2020

    Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study

    Nilasha Ghosh1, Aidan Tirpack2, Caroline Benson3, Gregory Vitone3, Karmela Kim Chan2 and Anne Bass1, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Hospital for Special Surgery, New York

    Background/Purpose: It is not known whether cancer patients being treated with immune checkpoint inhibitors (ICI) and/or immunosuppression are more vulnerable to SARS-CoV-2 or more apt…
  • Abstract Number: 1996 • ACR Convergence 2020

    Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study

    Kevin Winthrop1, Juan Vargas2, Edit Drescher3, Conrado Garcia4, Alan Friedman5, Jeffrey Enejosa5, Nasser Khan5, Yihan Li5, Justin Klaff5 and Alan Kivitz6, 1Oregon Health & Science University, Portland, OR, 2Quantum Research, Puerto Varas, Chile, 3Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, 4Hospital General de México "Dr. Eduardo Liceaga", Mexico, Mexico, 5AbbVie Inc., North Chicago, IL, 6Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA

    Background/Purpose: Pneumococcal vaccination is recommended in patients with RA who are receiving conventional synthetic/biologic DMARDs.1 Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to…
  • Abstract Number: 0450 • ACR Convergence 2020

    In Vitro Characterization of Inflammatory Arthritis Associated with Immune Check Point Inhibition

    Anne Sofie Sørensen1, Morten Nørgaard Andersen1, Kristian Juul-Madsen2, Cæcilie Deisting Skejø1, Henrik Schmidt1, Thomas Vorup-Jensen1 and Tue Wenzel Kragstrup1, 1Aarhus University, Aarhus, Denmark, 2Aarhus University, Aarhus, Midtjylland, Denmark

    Background/Purpose: During treatment with immune checkpoint inhibitors (ICI) such as the anti-PD-1 antibody pembrolizumab, 2-4% of cancer patients develop inflammatory arthritis as an immune-related adverse…
  • Abstract Number: 0859 • ACR Convergence 2020

    Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis

    Ed Vital1, Philippe Remy2, Luis Fernando Quintana Porras3, Laurent Chiche4, Dominique Chauveau5, Richard Furie6, Thomas Schindler7, Jay Garg8, Matthew Cascino8, Zahir Amoura9, Andrea Doria10, Cary Looney8 and Dario Roccatello11, 1University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2APHP Groupe Hospitalier Henri-Mondor, Creteil, France, 3Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 4Hôpital Européen, Marseille, France, 5Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, 6Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 7F. Hoffmann-La Roche Ltd., Basel, Switzerland, 8Genentech, Inc., South San Francisco, CA, 9Hôpital Pitié-Salpêtrière, Paris, 10University of Padua, Padua, Italy, 11S Giovanni Hospital, Univ of Turin, Turin, Italy

    Background/Purpose: Incomplete B-cell and plasmablast depletion, as measured using highly sensitive flow cytometry (HSFC), is associated with lower response rates following rituximab in SLE [1].…
  • Abstract Number: 1571 • ACR Convergence 2020

    Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy

    Sang Kim1, Jean Tayar2, Maria Suarez-Almazor3, Huifang Lu4, Yang-Zhi Zhao5, Margarita Divenko5, William Padron5, Emma Rodriguez5, Sattva Neelapu5, Jennifer Wang5, Amish Shah5, Nizar Tannir5, Don Gibbons5, Guillermo Garcia-Manero5, Hussein Tawbi5, Patrick Hwu5, Andrew Futreal5, Adi Diab5 and Roza Nurieva5, 1The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX, 2The University of Texas, MD Anderson Cancer Center, Houston, TX, 3University of Texas MD Anderson Cancer Center, Houston, TX, 4MD Anderson, Houston, TX, 5MD Anderson, Houston

    Background/Purpose: Despite of unprecedented clinical success in cancer therapeutics, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Arthritis-irAE can…
  • Abstract Number: 2043 • ACR Convergence 2020

    Identification and Validation of Citrulline Specific TCRs in CD4+T Cells in Rheumatoid Arthritis

    Ravi Kumar1, Niyaz Yoosuf2, Sanjay Boddul2, Christina Gerstner3, Sara Turcinov4, Anatoly Dubnovitsky5, Fredrik Wermeling2, Karine Chemin6 and Vivianne Malmström7, 1Division of Rheumatology, Department of Medicine, Stickholm, Stockholms Lan, Sweden, 2Division of Rheumatology, Department of Medicine, Stockholm, Sweden, 3Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, 5Karolinska Institutet, Stockholm, 6Division of Rheumatology, Department of Medicine, Stockholm, Stockholms Lan, Sweden, 7Karolinska Institutet, Stockholm, Stockholms Lan, Sweden

    Background/Purpose: Citrulline (cit) autoimmunity is central in rheumatoid arthritis (RA), including both anti-citrulline protein antibodies (ACPA) and autoreactive CD4+ T cells. While the ACPA are…
  • Abstract Number: 0451 • ACR Convergence 2020

    Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis

    Sophia Verspohl1, Tobias Holderried1, Charlotte Behning2, Peter Brossart1 and Valentin Schaefer3, 1Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 2Institute for Medical Biometrics, Informatics and Epidemiology (IMBIE), University Hospital Bonn, Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 3Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have improved cancer therapy [1] by inducing a higher immune system activity and subsequent attack of tumor cells. However, this effect…
  • Abstract Number: 0861 • ACR Convergence 2020

    Hydroxychloroquine Use Is Associated with Diminished Type I Interferon-related Pathways in Systemic Lupus Erythematosus Patients

    Samantha Slight-Webb1, Kevin Thomas1, Rufei Lu1, Susan Macwana1, Joan Merrill1, Cristina Arriens1, Eliza Chakravarty1, Teresa Aberle1, Holden Maecker2, Paul Utz3, Joel Guthridge1 and Judith James4, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, 3Stanford University School of Medicine, Stanford, CA, 4Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK

    Background/Purpose: Hydroxychloroquine (HCQ) has been used for decades to treat systemic lupus erythematosus (SLE) and is associated with decreased lupus flares and damage. However, despite…
  • Abstract Number: 1573 • ACR Convergence 2020

    Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors

    Kevin Lee1, Carrie Ye2 and Shokrollah Elahi3, 1Internal Medicine, University of Alberta, Edmonton, AB, Canada, 2Rheumatology, University of Alberta, Edmonton, AB, Canada, 3Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Immune checkpoint inhibitors (ICI) are novel treatments approved for various tumours including melanoma, lung and kidney. By interacting with immunoregulatory molecules (programmed death-1 (PD-1),…
  • Abstract Number: 0460 • ACR Convergence 2020

    Lymphocyte Clonal Expansion Distinguishes Different Forms of Uveitis

    Michael Paley1, Lynn Hassman1, Philip Ruzycki1, Ekaterina Esaulova1, Grace Paley1, Jennifer Laurent1, Luke Springer1, Lacey Feigl1, Maxim Artyomov1 and Wayne Yokoyama2, 1Washington University, Saint Louis, 2Washington University, St Louis, MO

    Background/Purpose: Anterior uveitis is a form of ocular inflammation associated with rheumatologic disease and can be categorized as granulomatous or non-granulomatous. Whether different ocular manifestations…
  • Abstract Number: 0862 • ACR Convergence 2020

    Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE

    Teun van Gelder1, Robert Huizinga2, Neil Solomons2 and Laura Lisk3, 1Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, 2Aurinia Pharmaceuticals, Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc., Victoria, BC, Canada

    Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…
  • Abstract Number: 1574 • ACR Convergence 2020

    Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review

    Nilasha Ghosh1, Karmela Kim Chan2, Bridget Jivanelli3 and Anne Bass1, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Hospital For Special Surgery, New York, NY, 3Hospital for Special Surgery, New York

    Background/Purpose: Although immune checkpoint inhibitor (ICI) cancer treatments are known to activate cytotoxic T-cells, autoantibodies may also contribute to the development of immune-related adverse events…
  • Abstract Number: 0462 • ACR Convergence 2020

    Lupus-like Autoimmunity and Increased Interferon Response in Patients with STAT3-deficient Hyper-IgE Syndrome

    Brian Dizon1, Rishi Goel2, Shuichiro Nakabo2, Amanda Urban2, Meryl Waldman2, Lilian Howard2, Dirk Darnell2, Munir Buhaya2, Sarfaraz Hasni3, Mariana Kaplan4, Alexandra Freeman2 and Sarthak Gupta1, 1National Institutes of Health, BETHESDA, MD, 2National Institutes of Health, Bethesda, 3Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD

    Background/Purpose: Autosomal dominant hyper-IgE syndrome (AD-HIES), also known as Job’s syndrome, is a rare primary immunodeficiency caused by dominant-negative loss-of-function (LOF) mutations in signal transducer…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.